

## **Strongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences**

February 25, 2016 7:32 AM ET

DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that Matthew Pauls, president and chief executive officer, is scheduled to present a corporate overview at two upcoming investor conferences in March.

### **Cowen and Company 36<sup>th</sup> Annual Health Care Conference**

Date: Tuesday, March 8, 2016

Time: 10:00 a.m. EST

Location: Boston, MA

### **28<sup>th</sup> Annual ROTH Conference**

Date: Monday, March 14, 2016

Time: 9:30 a.m. PST

Location: Dana Point, CA

Both presentations will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at [www.strongbridgebio.com](http://www.strongbridgebio.com).

### **About Strongbridge Biopharma**

Strongbridge Biopharma's strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing's syndrome. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for the treatment of acromegaly and designed to block the synthesis of growth hormone receptor (GHR), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors. COR-003 and COR-005 have received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration, and the Company is pursuing orphan designation for COR-004. Strongbridge Biopharma's intent is to independently commercialize its rare endocrine assets in key global markets.

Contacts:

Corporate and Media Relations  
Elixir Health Public Relations  
Lindsay Rocco  
+1 862-596-1304  
[lrocco@elixirhealthpr.com](mailto:lrocco@elixirhealthpr.com)

Investor Relations  
ICR Inc.  
Stephanie Carrington  
+1 646-277-1282  
[Stephanie.Carrington@icrinc.com](mailto:Stephanie.Carrington@icrinc.com)

USA  
900 Northbrook Drive  
Suite 200  
Trevose, PA 19053  
Tel. +1 610-254-9200  
Fax. +1 215-355-7389



Strongbridge Biopharma plc